Experimental & Molecular Medicine. Feb/28/2015; 47(3): e152

Published online Mar/19/2015

PMID: 25792220

PMC: 4351407

Science Direct: emm2014115

doi: 10.1038/emm.2014.115

Euodia sutchuenensis Dode extract stimulates osteoblast differentiation via Wnt/β-catenin pathway activation

Abstract

The Wnt/β-catenin pathway has a role in osteoblast differentiation and bone formation. We screened 100 plant extracts and identified an extract from Euodia sutchuenensis Dode (ESD) leaf and young branch as an effective activator of the Wnt/β-catenin pathway. ESD extract increased β-catenin levels and β-catenin nuclear accumulation in murine primary osteoblasts. The ESD extract also increased mRNA levels of osteoblast markers, including RUNX2, BMP2 and COL1A1, and enhanced alkaline phosphatase (ALP) activity in murine primary osteoblasts. Both ESD extract-induced β-catenin increment and ALP activation were abolished by β-catenin knockdown, confirming that the Wnt/β-catenin pathway functions in osteoblast differentiation. ESD extract enhanced terminal osteoblast differentiation as shown by staining with Alizarin Red S and significantly increased murine calvarial bone thickness. This study shows that ESD extract stimulates osteoblast differentiation via the Wnt/β-catenin pathway and enhances murine calvarial bone formation ex vivo.

Introduction

Given the rapid growth of global elderly populations, osteoporosis is becoming a major public health issue.¹ Low bone mineral density and structural deterioration of bone tissue in osteoporosis leads to disability and early mortality.^{2, 3} Current therapeutic strategies for osteoporosis treatment use anti-resorptive agents such as estrogen and bisphosphonates to inhibit osteoclast activity.^{4, 5} Although estrogen replacement therapy improves bone mineral density and reduces fracture incidence in early menopausal women, long-term estrogen use increases the risks of breast cancer, abnormal uterine bleeding and cardiovascular diseases.⁶ Bisphosphonates, another class of anti-resorptive drug, cause severe and incapacitating bone, joint and/or muscle pains;^{7, 8} long-term treatment leads to severe bone fractures due to the accumulation of microfractures.⁹

To address the limitations of anti-resorptive drugs that inhibit osteoclast activity, anabolic agents are considered as beneficial therapeutics for osteoporosis treatment.¹⁰ Anabolic agents increase osteoblast differentiation and proliferation,^{11, 12} which enhances bone mass, quality, strength and composition.^{13, 14} Parathyroid hormone drugs such as full-length and N-terminal (1–34) fragment of parathyroid hormone are bone anabolic agents approved by the US Food and Drug Administration or the European Union.¹⁵ However, parathyroid hormone drugs have adverse side effects that potentially increase osteosarcoma and hyperparathyroidism incidence.^{11, 16} Parathyroid hormone drugs are relatively expensive and should be taken as daily injections.¹⁷ There is a great need to discover novel anabolic agents for osteoporosis treatment.

The Wnt/β-catenin pathway increases osteoblast differentiation and subsequent bone formation.^{18, 19} Nuclear accumulation of stabilized β-catenin is an important indicator of osteoblast differentiation.^{20, 21} Inactivation of Axin2, a negative regulator of the Wnt/β-catenin pathway, promotes osteoblast proliferation and differentiation and matrix mineralization in vitro and in vivo.²² Activation of the Wnt/β-catenin pathway enhances Runx2 expression, which is a crucial transcription factor for osteoblast differentiation.^{23, 24} Therefore, discovery and development of drugs that activate the Wnt/β-catenin pathway is a promising approach for the development of novel osteoporosis therapies. Glycogen synthase kinase-3β inhibitors or antibodies against Wnt/β-catenin pathway antagonists, including sclerostin, secreted frizzled-related protein-1 and dickkopf-1, induce bone formation in mice, rats or humans.^{25, 26} None of these drugs are currently approved for clinical applications. Natural products, including plant extracts, are traditionally used to treat diseases and are often used for drug development owing to fewer side effects compared with those of synthetic compounds.²⁷ Plants such as Eurycoma longifolia and Labisia pumila are used as traditional East Asian medicines for bone diseases, including osteoporosis.²⁸

Here we screened 100 plant extracts for the ability to activate the Wnt/β-catenin pathway in HEK293 cells harboring a chromosomal Wnt/β-catenin signaling reporter and characterized the effects on osteoblast differentiation and murine calvarial bone formation. We identified an extract from the leaf and young branch of Euodia sutchuenensis Dode (ESD) as an activator of the Wnt/β-catenin pathway. Activation of the Wnt/β-catenin pathway by ESD extract was confirmed, and its effect on osteoblast differentiation was demonstrated using murine primary osteoblasts. The effect of ESD extract in bone formation was investigated by ex vivo measuring murine calvarial bone formation. These results show that ESD extract is a potential Wnt/β-catenin pathway agent that can be used for osteoporosis treatment.

Materials and methods

Materials

A library containing methanol extracts of 100 plants was purchased from International Biological Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. The library contained extracts from Vietnamese plants, including an extract from the leaf and young branch of ESD. Extracts were dissolved in dimethyl sulfoxide (DMSO; Sigma Aldrich, St Louis, MO, USA).

Cell culture

HEK293-reporter cells containing chromosomally integrated TCF reporter (TOPflash)²⁹ were grown in Dulbecco's Modified Eagle Medium (Gibco BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco BRL) and 100 U ml⁻¹ penicillin/streptomycin (Gibco BRL). Murine primary osteoblasts were obtained from 4-day-old imprinting control region mice. Calvaria were dissected and digested five times in sequence with 0.32 mg ml⁻¹ collagenase type II (Worthington, Lakewood, NJ, USA) for 20 min at 37 °C. Cells were cultured in α-minimal essential medium (Gibco BRL) supplemented with 10% fetal bovine serum and 100 U ml⁻¹ penicillin/streptomycin (Gibco BRL). For osteoblast cell differentiation, 50 μg ml⁻¹ ascorbic acid (Sigma Aldrich) and 10 mM β-glycerophosphate (Sigma Aldrich) were added to the α-minimal essential medium.

Luciferase reporter assay

HEK293-reporter cells were seeded at a density of 2.7 × 10⁴ cells per well in 96-well white polystyrene plates (Greiner Bio-One, Stonehouse, UK). Cells were treated with each plant extract, DMSO (negative control) or Hovenia dulcis Thunb. (HDT, positive control³⁰) at a final concentration of 5 μg ml⁻¹ for 24 h. TOPflash reporter activity was measured as described previously,²⁹ and relative reporter activity was calculated by normalizing to the DMSO negative control. For quantitative analysis of TOPflash reporter activity induced by ESD extract, HEK293-reporter cells were seeded in 24-well plate at a density of 7 × 10⁴ cells per well, and cells were treated with ESD extract (1 or 5 μg ml⁻¹) for 24 h. Total cell lysates were extracted with 55 μl of 5 × Reporter Lysis Buffer (Promega, Madison, WI, USA) per well. Next, 15 μl of luciferin was added to 30 μl of cell lysate, and luciferase activity was measured using the FLUOstar Optima plate reader (BMG Labtech, Offenburg, Germany).

Cell viability assay

Murine primary osteoblasts were seeded in 24-well plates at a density of 2.5 × 10⁴ cells per well and treated with DMSO or ESD extract for 72 h. Next, 0.25 mg ml⁻¹ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Amresco, Solon, OH, USA) was added to each well, cells were incubated for 2 h at 37 °C, and the insoluble formazan product was obtained by removal of the medium. The formazan product was dissolved by adding 1 ml DMSO for 30 min and then quantitated by reading the absorbance at 590 nm.³⁰

Immunoblotting

Murine primary osteoblasts were rinsed with ice-cold phosphate-buffered saline (PBS; Gibco BRL), lysed in 70 μl of radioimmunoprecipitation assay buffer (Millipore, Bedford, MA, USA), incubated for 10 min at 4 °C and centrifuged at 15 920 g for 30 min. Proteins were separated to 8% sodium dodecyl sulphate–polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Whatman, Florham Park, NJ, USA). Next, proteins were incubated with the following primary antibodies: anti-β-catenin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-α-tubulin (Oncogene Research Products, Cambridge, MA, USA). Secondary antibody was horseradish peroxidase-conjugated anti-mouse (Cell Signaling, Beverly, MA, USA) or anti-rabbit (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were visualized using enhanced chemiluminescence (Amersham Bioscience, Piscataway, NJ, USA) and a luminescent image analyzer (LAS-3000; Fujifilm, Tokyo, Japan).

Immunocytochemistry

Murine primary osteoblasts were seeded on glass coverslips in a 12-well plate at a density of 4 × 10⁴ cells per well and treated with DMSO or ESD extract for 24 h at 37 °C. Next, cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.1% Triton X-100 for 15 min. Cells were blocked with 5% bovine serum albumin for 1 h and incubated with anti-β-catenin antibody (Santa Cruz Biotechnology) overnight at 4 °C. Cells were then rinsed with PBS, incubated with anti-mouse Alexa Flour 488 (Life Technologies, Carlsbad, CA, USA) secondary antibody for 1 h and counterstained with 4′,6-diamidino-2-phenylindole (Sigma Aldrich). Cell fluorescence was observed and captured using a confocal microscope (LSM510; Carl Zeiss Inc., Thornwood, NY, USA). Measurement of β-catenin fluorescence intensity was performed using the NIS elements AR 3.1 software (Nikon, Tokyo, Japan).

RNA extraction and quantitative real-time PCR

For RNA extraction, murine primary osteoblasts were seeded in six-well plates at a density of 9 × 10⁴ cells per well and cultured for 2 days. Next, ESD extract in differentiation medium was added, and cells were incubated for 48 h as described in the Cell culture section. Total RNA was prepared using TRIzol (Invitrogen, Carlsbad, CA, USA), and 4 μg of total RNA was reverse transcribed into cDNA using 200 U of reverse transcriptase (Invitrogen) according to the manufacturer's instructions. The gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression as a house keeping gene. The following primers were used: bone morphogenetic protein 2 (BMP2), forward 5′-ATCCAGTCTTGCCGCCTC-3′ and reverse 5′-GCCTCCTCCTCCTTCTCC-3′ runt-related transcription factor 2 (RUNX2), forward 5′-AAGGACAGAGTCAGATTACAGA-3′ and reverse 5′-GTGGTGGAGTGGATGGAT-3′ collagen type I alpha 1 (COL1A1), forward 5′-GGTCTTCCAGGTCCTAAGG-3′ and reverse 5′-CACGGGCACCATCTTTAC-3′ and GAPDH, forward 5′-CCATGGAGAAGGCTGGGG-3′ and reverse 5′-CAAAGTTGTCATGGATGACC-3′.

Alkaline phosphatase (ALP) staining

Murine primary osteoblasts were seeded at a density of 5 × 10⁴ cells per well in a 24-well plate and cultured for 2 days. Next, ESD extract in differentiation medium was added, and cells were incubated for 48 h as described in the Cell culture section. For the ALP staining assay, ALP activites were visualized using the TRACP and ALP Double-Stain kit (Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. Images were visualized with a bright field optical microscope (Eclipse TE2000-U; Nikon).

ALP assay

Murine primary osteoblasts were seeded in a 24-well plate at a density of 5 × 10⁴ cells per well and cultured for 2 days. Next, ESD extract in differentiation medium was added, and cells were incubated for 48 h as described in the Cell culture section. To measure ALP activity, cells were rinsed with PBS and lysed with 55 μl of 5 × Reporter Lysis Buffer (Promega) per well. Cells were incubated for 10 min at 4 °C and centrifuged at 15 920 g for 30 min at 4 °C. The supernatant (20 μl) was incubated with 100 μl Tris-glycine buffer pH 10.3 (50 mM Tris-HCl (Amresco), 100 mM glycine (Duksan, Ansan, Gyeonggido, Korea) and 2 mM MgCl₂ (Duksan)) and 100 μl of p-nitrophenyl phosphate (Sigma Aldrich). The reaction was stopped with 50 μl of 3 M NaOH, and the absorbance was measured at 405 nm.³¹ ALP activity was quantified by measuring the protein concentration using the Bradford assay (Bio-Rad Laboratories).

Alizarin Red S staining

Murine primary osteoblasts were seeded in a 24-well plate at a density of 5 × 10⁴ cells per well and cultured for 2 days. Next, ESD extract in differentiation medium was added, and cells were incubated for 14 days as described in the Cell culture section. Medium was changed every 2 days. After 14 days, cells were rinsed with cold PBS, fixed with 4% paraformaldehyde for 20 min at room temperature and stained with 2% Alizarin red S staining solution (pH 4.2; Sigma Aldrich) for 30 min at room temperature. For quantification, Alizarin Red was solubilized with 10% acetic acid, followed by heating at 85 °C for 10 min. The eluates were neutralized in 10% ammonium hydroxide. The quantity of Alizarin Red was measured spectrophotometrically at 405 nm.²⁶ Images were recorded with a bright field optical microscope (Eclipse TE2000-U; Nikon).

Calvaria ex vivo culture and hematoxylin and eosin staining

Calvaria isolated from 4-day-old imprinting control region mice were grown in a 12-well plate with α-minimal essential medium for 24 h and treated with ESD extract in differentiation medium for 7 days. Medium was changed every 2 days. Calvaria were fixed in 4% paraformaldehyde for 2 days and then decalcified in 4% formic acid and 4% hydrochloric acid for 2 days at 4 °C. Next, calvaria were embedded in paraffin, sectioned in 4-μm thickness (Leica Microsystems, Wetzlar, Germany). The 4-μm bone tissue sections were deparaffinized in xylene and in a graded ethanol series and used for hematoxylin and eosin orange G staining. The hematoxylin and eosin-stained preparations were visualized with a bright field optical microscope (Eclipse TE2000-U; Nikon).

Immunohistochemistry

For florescence immunohistochemistry analyses, the 4-μm bone tissue sections were deparaffinized in xylene and in a graded ethanol series and incubated for 4 h at 60 °C in sodium citrate buffer (10 mM sodium citrate, pH 6.0) for antigen retrieval. The sections were blocked in 5% bovine serum albumin and 1% goat serum in PBS at room temperature for 1 h and then incubated with primary antibody anti-β-catenin (Santa Cruz Biotechnology) and secondary antibody anti-mouse Alexa Flour 555 (Life Technologies). The sections were stained with 4′,6-diamidino-2-phenylindole and mounted in Gel/Mount medium (Biomeda Corporation, Foster City, CA, USA). A confocal microscopy (LSM510; Carl Zeiss Inc.) observed and captured fluorescence.³⁰

β-Catenin knockdown mediated by small interfering RNA (siRNA) transfection

Murine primary osteoblasts were seeded in six-well plates at a density of 1 × 10⁵ cells per well. The cells were transfected with siRNA for β-catenin or negative control (Bioneer, Daejeon, Korea) using Lipofectamine Plus (Invitrogen) in serum-free Opti-MEM (Gibco BRL) according to the manufacturer's instructions. After 12-h transfection with β-catenin siRNA, ESD extract in differentiation medium was added, and cells were incubated for 48 h before harvesting. ALP assay and immunoblotting were performed to examine changes in ALP activity and to confirm the transfection efficiency of β-catenin siRNA.

Statistical analyses

Each experiment was performed at least three times, and results were presented as means±s.d. Statistical significance was analyzed using the Student's t-test for experiments involving two groups. P-values <0.05 were considered statistically significant (*P<0.05, **P<0.01, ***P<0.001).

Results

Identification of ESD extract as a Wnt/β-catenin pathway activator

We screened a library containing methanol extracts of 100 plants using HEK293-reporter cells to identify plant extracts that stimulate the Wnt/β-catenin pathway (Figure 1a). ESD and Impatiens eberhardtii Tardieu extracts produced >140% TOPflash reporter activity compared with that of control (Figure 1a). We selected ESD extract for further analysis due to 15% greater increase in TOPflash activity compared with that of Impatiens eberhardtii Tardieu or HDT (positive control) (Figure 1b).³⁰ Furthermore, ESD extract increased TOPflash activity in a dose-dependent manner (Figure 1c).

ESD extract activates the Wnt/β-catenin pathway in murine primary osteoblasts

ESD extract is not significantly toxic to murine primary osteoblasts (Figure 2a). To investigate whether ESD extract activates the Wnt/β-catenin pathway in murine primary osteoblasts, we examined β-catenin levels in murine primary osteoblasts treated with the ESD extract. ESD extract increased β-catenin levels in murine primary osteoblasts in a dose-dependent manner as determined by immunoblotting and immunocytochemistry (Figures 2b–d). Nuclear accumulation of β-catenin was elevated in murine primary osteoblasts treated with the ESD extract (Figures 2c and e). Together, these results indicate that ESD extract induces Wnt/β-catenin pathway activation in murine primary osteoblasts.

ESD extract stimulates murine primary osteoblast differentiation via Wnt/β-catenin pathway activation

As activation of the Wnt/β-catenin pathway induces osteoblast differentiation, we examined the effect of ESD extract on murine primary osteoblast differentiation. Transcriptional levels of osteogenic differentiation marker genes such as BMP2, RUNX2 and COL1A1 were approximately 1.5- to 2-fold higher after treatment with ESD extract compared with those of controls (Figure 3a). ESD extract also enhanced ALP activity as determined by ALP staining and direct measurement of ALP activity (Figures 3b and c). Furthermore, ESD extract enhanced terminal osteoblast differentiation as determined by Alizarin Red S staining in murine primary osteoblasts (Figures 4a and b).

To verify Wnt/β-catenin pathway activation in ESD extract-induced osteogenic differentiation, we measured the effects of ESD extract on osteogenic differentiation of murine primary osteoblasts when β-catenin was knocked down. ESD extract-enhanced ALP activity was abolished by β-catenin knockdown (Figures 5a and b). Taken together, these results indicate that ESD extract activates osteoblast differentiation by upregulating the Wnt/β-catenin pathway.

ESD extract increases murine calvarial thickness ex vivo

To investigate whether ESD extract-induced osteogenic differentiation in vitro promoted bone formation ex vivo, calvaria isolated from 4-day-old mice were treated with ESD extract for 7 days. Hematoxylin and eosin staining showed that ESD extract significantly increased the thickness of murine calvarial bone in an ex vivo culture system (Figures 6a and b). ESD extract increased the number of β-catenin-positive cells (Figures 6c and d) in murine calvaria. These results indicate that ESD extract enhances murine calvarial bone formation ex vivo together with activation of the Wnt/β-catenin pathway.

Discussion

Bone remodeling is a dynamic and continuous process that maintains a constant bone mass.³² It is regulated by a balance between osteoblast-mediated formation of new bone and osteoclast-mediated removal of old bone.^{3, 33} An imbalance in bone formation and resorption causes bone-related diseases, including osteoporosis. Bone density tends to decrease during aging,³⁴ leading to weaker bone, elevated bone loss and greater risk of catastrophic bone fracture. Postmenopausal estrogen deficiency frequently leads to accelerated bone loss and osteoporosis in women.³⁵ Age-related and postmenopausal osteoporosis is commonly associated with osteoblast dysfunction.^{36, 37} Conversely, stimulating osteoblast function promotes bone formation and increases bone strength.³⁸ New therapeutic approaches for osteoporosis require identification and development of new anabolic agents that improve bone mass by stimulating osteoblast activity.³⁹

Several signaling pathways regulate osteoblast differentiation, including Wnt,^{18, 19} parathyroid hormone⁴⁰ and bone morphogenic protein.⁴¹ The role of Wnt/β-catenin signaling in osteoblast differentiation and bone formation has attracted considerable interest in recent years.²⁵ Aberrant activation of the Wnt/β-catenin pathway is implicated in tumorigenesis;⁴² however, a recent report shows that this pathway is inactive in osteosarcoma cell lines.⁴³ Activation of the Wnt/β-catenin pathway stimulates osteogenic differentiation and inhibits cell proliferation in osteosarcoma cell lines.⁴³ Therefore, identification of drugs that directly activate the Wnt/β-catenin pathway is a promising approach to identify drugs for anabolic bone formation.

We screened a library of plant extracts and identified an extract from the leaf and young branch of ESD as an effective activator of the Wnt/β-catenin pathway. ESD is an ornamental tree that belongs to Rutaceae, occurring in temperate regions. In Korea and China, ESD has been used as a herbal medicine to relieve headache, gastric inflammation and dermatitis.⁴⁴ ESD has also been reported to have anti-feedant activity mediated by the linear furanocoumarins and anti-mycobacterial activity mediated by the geranylated furanocoumarins isolated from its fruits.^{45, 46} However, the effect of ESD on osteoblast differentiation has not been revealed. ESD extract-induced osteoblast differentiation was confirmed by ALP activation and induction of RUNX2, BMP2 and COL1A1 expression. The effect of ESD extract on bone formation was further confirmed by enhanced mineralization and calvarial bone formation. The function of ESD extract in bone formation was verified ex vivo by measuring the number of β-catenin-positive cells in murine calvaria (Figures 5c and d). The leaf of ESD contains ingredients such as evodioside B, hesperidin, limonin, simplexoside, vitexin, uracil and myo-inositol.⁴⁷ Hesperidin is a monomethoxylated flavanone that exists in citrus fruits, and several studies have shown that hesperidin inhibits bone loss.^{48, 49} Myo-inositol has been reported to have essential roles in osteogenesis and bone formation.⁵⁰ Therefore, it is possible that hesperidin and myo-inositol in ESD may have roles in the enhancement of osteogenic differentiation.

Taken together, our data show that ESD extract stimulates osteoblast differentiation in vitro, increases the thickness of mice calvarial bone ex vivo and activates Wnt/β-catenin signaling. These results suggest that ESD extract might have therapeutic potential for clinical treatment of osteoporosis.

Figure 1

Screening of a library of 100 plant extracts for Wnt/β-catenin pathway activators. HEK293-reporter cells were treated with extracts for 24 h, and cell lysates were subjected to TOPflash reporter assay (n=3). (a) A library of 100 plant extracts was screened. (b) HEK293-reporter cells were treated with extracts from Euodia sutchuenensis Dode (ESD) or Impatiens eberhardtii Tardieu (IET), which produced >140% TOPflash activity compared with controls; Hovenia dulcis Thunb. (HDT) extract was used as a positive control. (c) HEK293-reporter cells were treated with the ESD extract at different concentrations, and activation of the Wnt/β-catenin pathway was measured. **P<0.01, ***P<0.001 versus control.

Figure 2

Effects of ESD extract on activation of the Wnt/β-catenin pathway in murine primary osteoblasts. (a) Murine primary osteoblasts were treated with various ESD extract concentrations for 72 h, and cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (n=3). (b–e) Murine primary osteoblasts were treated with 0, 1 or 5 μg ml⁻¹ of ESD extract for 24 h. (b) Immunoblotting analysis was performed to detect β-catenin and α-tubulin. (c) Immunofluorescence staining was performed to detect β-catenin (green). Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole; blue). White arrows indicate nuclear localization of β-catenin. Scale bars=100 μm. (d) Quantitative analyses of total β-catenin intensity. (e) Quantitative analysis of β-catenin nuclear accumulation (n>3). **P<0.01, ***P<0.001 versus control.

Figure 3

Effects of ESD extract on osteogenic differentiation of murine primary osteoblasts. (a–c) Murine primary osteoblasts were treated with 5 μg ml⁻¹ ESD extract or DMSO (control) in differentiation medium for 48 h. (a) Real-time reverse transcriptase-PCR assay was performed to examine changes in osteoblast marker gene expression, RUNX2, BMP2 and COL1A1. Relative gene expression was normalized to GAPDH expression (n=3). (b) Cells were subjected to alkaline phosphatase (ALP) staining. (c) Cells were subjected to ALP activity measurement; ALP activity was normalized with respect to total protein concentration. *P<0.05, **P<0.01 versus control.

Figure 4

Effects of ESD extract on terminal osteogenic differentiation of murine primary osteoblasts. (a, b) Murine primary osteoblasts were treated with ESD extract for 14 days. (a) Matrix mineralization was visualized by Alizarin Red S staining. (b) Alizarin Red S staining was quantified by measuring absorbance at 450 nm. *P<0.05 versus control.

Figure 5

Effects of ESD extract on osteogenic differentiation of murine primary osteoblasts via Wnt/β-catenin pathway activation. (a–b) Murine primary osteoblasts were transfected with β-catenin siRNA or control siRNA for 12 h and then treated with 5 μg ml⁻¹ ESD extract in differentiation media for 48 h. (a) Immunoblotting analyses were performed to detect β-catenin and α-tubulin. (b) Cells were subjected to ALP activity measurement; ALP activity was normalized with respect to the total protein concentration (n>3). **P<0.01 versus control.

Figure 6

Effects of ESD extract on murine calvaria bone formation ex vivo. (a–d) Murine calvaria were treated with 5 μg ml⁻¹ ESD extract in osteogenic differentiation medium for 7 days. (a) Hematoxylin and eosin staining was performed to evaluate calvaria (original magnification × 400). (b) Bone thickness was quantified (n=3). (c) Calvaria were fluorescently stained for β-catenin. White arrows indicate β-catenin-positive cells. Scale bars=100 μm. (d) β-Catenin-positive cells were quantified as the number of β-catenin-positive cells divided by the total number of cells (n>3). *P<0.05, **P<0.01 versus control.

Acknowledgments

This work was supported by grants from the National Research Foundation (NRF) funded by the Ministry of Education, Science and Technology of Korea (the Mid-career Researcher Program (2012-010285), Translational Research Center for Protein Function Control; 2009-0083522) and Stem Cell Research Project (2010-0020235). This work was also supported by a grant from the Korea Research Institute of Chemical Technology (SI-095). J-H Hwang was supported by a BK21 scholarship from the Ministry of Education and Human Resources Development.

References

1. CheungAMFeigDSKapralMDiaz-GranadosNDodinSCanadian Task Force on Preventive Health Care. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health CareCMAJ200417016651667[PubMed][Google Scholar]
2. OldJLCalvertMVertebral compression fractures in the elderlyAm Fam Physician200469111116[PubMed][Google Scholar]
3. KhoslaSRiggsBLPathophysiology of age-related bone loss and osteoporosisEndocrinol Metab Clin North Am20053410151030[PubMed][Google Scholar]
4. HellsteinJWAdlerRAEdwardsBJacobsenPLKalmarJRKokaSManaging the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific AffairsJ Am Dent Assoc201114212431251[PubMed][Google Scholar]
5. LeeYJJeongJKSeolJWXueMJacksonCParkSYActivated protein C differentially regulates both viability and differentiation of osteoblasts mediated by bisphosphonatesExp Mol Med201345e9[PubMed][Google Scholar]
6. TangDZHouWZhouQZhangMHolzJSheuTJOsthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signalingJ Bone Miner Res20102512341245[PubMed][Google Scholar]
7. LicataAADiscovery, clinical development, and therapeutic uses of bisphosphonatesAnn Pharmacother200539668677[PubMed][Google Scholar]
8. RotellaDPOsteoporosis: challenges and new opportunities for therapyCurr Opin Drug Discov Devel20025477486[Google Scholar]
9. KennelKADrakeMTAdverse effects of bisphosphonates: implications for osteoporosis managementMayo Clin Proc200984632637quiz 638.[PubMed][Google Scholar]
10. GuoAJChoiRCCheungAWChenVPXuSLDongTTBaicalin, a flavone, induces the differentiation of cultured osteoblasts: an action via the Wnt/beta-catenin signaling pathwayJ Biol Chem20112862788227893[PubMed][Google Scholar]
11. KhanAWKhanAAnabolic agents: a new chapter in the management of osteoporosisJ Obstet Gynaecol Can200628136141[PubMed][Google Scholar]
12. TangDZYangFYangZHuangJShiQChenDPsoralen stimulates osteoblast differentiation through activation of BMP signalingBiochem Biophys Res Commun2011405256261[PubMed][Google Scholar]
13. SosaMGonzález-PadillaEPromising developments in osteoporosis treatmentInt J Clin Rheumatol20116325332[Google Scholar]
14. SibaiTMorganEFEinhornTAAnabolic agents and bone qualityClin Orthop Relat Res201146922152224[PubMed][Google Scholar]
15. RachnerTDKhoslaSHofbauerLCOsteoporosis: now and the futureLancet201137712761287[PubMed][Google Scholar]
16. TashjianAHJrGagelRFTeriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosisJ Bone Miner Res200621354365[PubMed][Google Scholar]
17. GarrettIRAnabolic agents and the bone morphogenetic protein pathwayCurr Top Dev Biol200778127171[PubMed][Google Scholar]
18. LiuFKohlmeierSWangCYWnt signaling and skeletal developmentCell Signal2008209991009[PubMed][Google Scholar]
19. PitersEBoudinEVan HulWWnt signaling: a win for boneArch Biochem Biophys2008473112116[PubMed][Google Scholar]
20. BaronRRawadiGRoman-RomanSWnt signaling: a key regulator of bone massCurr Top Dev Biol200676103127[PubMed][Google Scholar]
21. ZhangJZhangXZhangLZhouFvan DintherMTen DijkePLRP8 mediates Wnt/beta-catenin signaling and controls osteoblast differentiationJ Bone Miner Res20122720652074[PubMed][Google Scholar]
22. YuHMJerchowBSheuTJLiuBCostantiniFPuzasJEThe role of Axin2 in calvarial morphogenesis and craniosynostosisDevelopment200513219952005[PubMed][Google Scholar]
23. GaurTLengnerCJHovhannisyanHBhatRABodinePVKommBSCanonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expressionJ Biol Chem20052803313233140[PubMed][Google Scholar]
24. KomoriTRegulation of skeletal development by the Runx family of transcription factorsJ Cell Biochem200595445453[PubMed][Google Scholar]
25. HoeppnerLHSecretoFJWestendorfJJWnt signaling as a therapeutic target for bone diseasesExpert Opin Ther Targets200913485496[PubMed][Google Scholar]
26. ZahoorMChaPHMin doSChoiKYIndirubin-3'-oxime reverses bone loss in ovariectomized and hindlimb-unloaded mice via activation of the Wnt/beta-catenin signalingJ Bone Miner Res20142911961205[PubMed][Google Scholar]
27. NewmanDJCraggGMNatural products as sources of new drugs over the 30 years from 1981 to 2010J Nat Prod201275311335[PubMed][Google Scholar]
28. Abd JalilMAShuidANMuhammadNRole of medicinal plants and natural products on osteoporotic fracture healingEvid Based Complement Alternat Med20122012714512[PubMed][Google Scholar]
29. YunMSKimSEJeonSHLeeJSChoiKYBothERKand Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferationJ Cell Sci2005118313322[PubMed][Google Scholar]
30. ChaPHShinWZahoorMKimHYMin doSChoiKYHovenia dulcis Thunb extract and its ingredient methyl vanillate activate Wnt/beta-catenin pathway and increase bone mass in growing or ovariectomized micePLoS One20149e85546[PubMed][Google Scholar]
31. Sila-AsnaMBunyaratvejAMaedaSKitaguchiHBunyaratavejNOsteoblast differentiation and bone formation gene expression in strontium-inducing bone marrow mesenchymal stem cellKobe J Med Sci2007532535[PubMed][Google Scholar]
32. KimWKKimJCParkHJSulOJLeeMHKimJSPlatinum nanoparticles reduce ovariectomy-induced bone loss by decreasing osteoclastogenesisExp Mol Med201244432439[PubMed][Google Scholar]
33. RodanGABone homeostasisProc Natl Acad Sci USA1998951336113362[PubMed][Google Scholar]
34. ChungPLZhouSEslamiBShenLLeboffMSGlowackiJEffect of age on regulation of human osteoclast differentiationJ Cell Biochem201411514121419[PubMed][Google Scholar]
35. MiyauchiYSatoYKobayashiTYoshidaSMoriTKanagawaHHIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosisProc Natl Acad Sci USA20131101656816573[PubMed][Google Scholar]
36. KassemMMariePJSenescence-associated intrinsic mechanisms of osteoblast dysfunctionsAging Cell201110191197[PubMed][Google Scholar]
37. AlbrightFSmithPHRichardsonAMPostmenopausal osteoporosis: its clinical featuresJAMA194111624652474[Google Scholar]
38. MariePJKassemMOsteoblasts in osteoporosis: past, emerging, and future anabolic targetsEur J Endocrinol2011165110[PubMed][Google Scholar]
39. LaneNEKelmanAA review of anabolic therapies for osteoporosisArthritis Res Ther20035214222[PubMed][Google Scholar]
40. IsogaiYAkatsuTIshizuyaTYamaguchiAHoriMTakahashiNParathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stagesJ Bone Miner Res19961113841393[PubMed][Google Scholar]
41. YamaguchiAIshizuyaTKintouNWadaYKatagiriTWozneyJMEffects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6Biochem Biophys Res Commun1996220366371[PubMed][Google Scholar]
42. LuuHHZhangRHaydonRCRayburnEKangQSiWWnt/beta-catenin signaling pathway as a novel cancer drug targetCurr Cancer Drug Targets20044653671[PubMed][Google Scholar]
43. CaiYMohsenyABKarperienMHogendoornPCZhouGCleton-JansenAMInactive Wnt/beta-catenin pathway in conventional high-grade osteosarcomaJ Pathol20102202433[PubMed][Google Scholar]
44. WiartCLead Compounds from Medicinal Plants for the Treatment of Neurodegenerative DiseasesAcademic Press: London, UK2014
45. StevensonPCSimmondsMSYuleMAVeitchNCKiteGCIrwinDInsect antifeedant furanocoumarins from Tetradium danielliiPhytochemistry2003634146[PubMed][Google Scholar]
46. AdamsMEttlSKunertOWubeAAHaslingerEBucarFAntimycobacterial activity of geranylated furocoumarins from Tetradium danielliiPlanta Med20067211321135[PubMed][Google Scholar]
47. YooSWKimJSKangSSSonKHChangHWKimHPConstituents of the fruits and leaves of Euodia danielliiArch Pharm Res200225824830[PubMed][Google Scholar]
48. HorcajadaMNHabauzitVTrzeciakiewiczAMorandCGil-IzquierdoAMardonJHesperidin inhibits ovariectomized-induced osteopenia and shows differential effects on bone mass and strength in young and adult intact ratsJ Appl Physiol (1985)2008104648654[PubMed][Google Scholar]
49. ChibaHKimHMatsumotoAAkiyamaSIshimiYSuzukiKHesperidin prevents androgen deficiency-induced bone loss in male micePhytother Res201428289295[PubMed][Google Scholar]
50. DaiZChungSKMiaoDLauKSChanAWKungAWSodium/myo-inositol cotransporter 1 and myo-inositol are essential for osteogenesis and bone formationJ Bone Miner Res201126582590[PubMed][Google Scholar]